Further investigation of the revealed founder variants in other cancers in Kazakhs could lead to overlapping results, as these PVs cause truncated or absent BRCA1 and BRCA2 proteins and have already been found in other malignancies where loss of function is a known disease mechanism. Here, BRCA2 is linked to cancer.